Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 25/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: Ultragenyx Pharmaceutical Inc. is facing a securities class action lawsuit after disclosing that its Phase III studies for setrusumab failed to demonstrate significant efficacy in treating osteogenesis imperfecta. Due to this announcement on December 26, 2025, the company's shares plummeted approximately 42% in value. Investors who suffered losses exceeding $100,000 during the class period from August 3, 2023, to December 26, 2025, have until April 6, 2026, to file lead plaintiff applications. The lawsuit claims that the company violated federal securities laws by failing to disclose material information.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx's Phase III studies for setrusumab failed to demonstrate a significant reduction in fracture rates.
  • The company's shares dropped 42% following the negative study results, indicating severe investor reaction.
  • Investors are urged to file claims due to material information failures by the company during the class period.

Full Press Release Details

NEW ORLEANS, March 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is ClaimsFiler and its purpose?

ClaimsFiler is a free service that helps investors recover funds from securities class action settlements.

What is the deadline for filing lead plaintiff applications?

Investors must file lead plaintiff applications by April 6, 2026.

What lawsuit is related to Ultragenyx Pharmaceutical?

The lawsuit addresses Ultragenyx's failure to disclose key information during the Class Period.

Why did Ultragenyx's shares drop significantly?

Shares fell 42% after the Phase 3 study results for setrusumab did not meet expectations.

Where can investors find more information?

Investors can visit https://claimsfiler.com/cases/nasdaq-rare/ for more details.

Last updated: Mar 26, 2026